Hypercoagulability After Breast Cancer Surgery

The risk of deep venous thrombosis after radical breast surgery is known. The objective of this study is to explore hypercoagulability after radical breast cancer surgery by studying several factors for haemostasis before, during and after surgery. Ultrasound Doppler examination is realised between 24 and 72 hours post-operatively. Hypercoagulability is defined by a significant increasing level of thrombin-antithrombin, D-dimer and the endogen thrombin potential.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Blood Coagulation Disorders Breast Diseases Breast Neoplasms Hematologic Diseases Hemic and Lymphatic Diseases Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases Thrombophilia

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Institut Bergonié - Centre Régional de Luttre Contre le Cancer de Bordeaux et du Sud Ouest

Bordeaux, 33076, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Breast cancer
mastectomy

Exclusion criteria

thrombophilia
anticoagulant treatment

Treatment and study plan

Blood collection (pre and postoperative): plasma coagulation parameters

Procedure

Sponsors and collaborators

Lead sponsor

Institut Bergonié

Other

Registry information

Official study title

Plasma Coagulation Parameters and Hypercoagulability After Breast Cancer Surgery

Acronym: EHC

Important dates

Study start: 2005
Study completion: 2006
First posted: Sep 21, 2005
Registry last updated: Jul 26, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed